The Time to Reconsider Mineralocorticoid Receptor Blocking Strategy: Arrival of Nonsteroidal Mineralocorticoid Receptor Blockers

Overview

Journal Curr Hypertens Rep

Specialty Cardiology & Vascular Diseases

Date 2022 Apr 30

PMID 35488944

Authors

Yuta Tezuka

Sadayoshi Ito

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: The study aims to verify the advantages of nonsteroidal mineralocorticoid receptor blockers (MRBs) in the management of hypertension and cardiovascular and renal diseases, comparing with conventional MRBs.

Recent Findings: Based on the unique structures, the nonsteroidal MRBs have higher selectivity for mineralocorticoid receptors (MRs) and show no agonist activity for major steroid hormone receptors in contrast to steroidal MRBs. Today, there are two nonsteroidal MRBs, esaxerenone and finerenone, which completed phase 3 clinical trials. Series of clinical trials have shown that both agents achieve similar MR blockade with smaller doses as compared with steroidal MRBs, but have no off-target side effect such as gynecomastia. Esaxerenone has persistent blood pressure-lowering effects in various hypertensive populations, including essential hypertension and those with diabetes and/or chronic kidney disease, while finerenone has demonstrated reduction of the cardiovascular risk rather than blood pressure in patients with diabetes and chronic kidney disease. Nonsteroidal MRBs are a more refined agent which contributes to appropriate MR blocking with minimized unpleasant adverse effects.

Citing Articles

Efficacy of Mineralocorticoid Receptor Antagonists on Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: An Umbrella Review.

Amornritvanich P, Anothaisintawee T, Attia J, Mckay G, Thakkinstian A Kidney Med. 2025; 7(2):100943.

PMID: 39926029 PMC: 11803877. DOI: 10.1016/j.xkme.2024.100943.

Hyperkalemic effect of drug-drug interaction between esaxerenone and trimethoprim in patients with hypertension: a pilot study.

Hirai T, Ueda S, Ogura T, Katayama K, Dohi K, Kondo Y J Pharm Health Care Sci. 2024; 10(1):46.

PMID: 39090747 PMC: 11295366. DOI: 10.1186/s40780-024-00366-6.

Mineralocorticoid Receptor and Aldosterone: Interaction Between NR3C2 Genetic Variants, Sex, and Age in a Mixed Cohort.

Heydarpour M, Parksook W, Pojoga L, Williams G, Williams J J Clin Endocrinol Metab. 2024; 110(1):e140-e149.

PMID: 38437868 PMC: 11651684. DOI: 10.1210/clinem/dgae127.

Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.

Yamamoto E, Usuku H, Sueta D, Suzuki S, Nakamura T, Matsui K Adv Ther. 2024; 41(3):1284-1303.

PMID: 38310194 PMC: 10879332. DOI: 10.1007/s12325-024-02780-6.

The Mineralocorticoid Receptor on Smooth Muscle Cells Promotes Tacrolimus-Induced Renal Injury in Mice.

Figueroa S, Bertocchio J, Nakamura T, El-Moghrabi S, Jaisser F, Amador C Pharmaceutics. 2023; 15(5).

PMID: 37242615 PMC: 10223994. DOI: 10.3390/pharmaceutics15051373.

References

Arai K, Tsuruoka H, Homma T . CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2015; 769:266-73. DOI: 10.1016/j.ejphar.2015.11.028. View

Ito S, Kashihara N, Shikata K, Nangaku M, Wada T, Okuda Y . Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial. Clin J Am Soc Nephrol. 2020; 15(12):1715-1727. PMC: 7769030. DOI: 10.2215/CJN.06870520. View

Duggan S . Esaxerenone: First Global Approval. Drugs. 2019; 79(4):477-481. DOI: 10.1007/s40265-019-01073-5. View

Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M . Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. Drug Metab Dispos. 2018; 46(11):1546-1555. DOI: 10.1124/dmd.118.083337. View

Epstein M, Williams G, Weinberger M, Lewin A, Krause S, Mukherjee R . Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2007; 1(5):940-51. DOI: 10.2215/CJN.00240106. View

Ferreira J, Rossello X, Eschalier R, McMurray J, Pocock S, Girerd N . MRAs in Elderly HF Patients: Individual Patient-Data Meta-Analysis of RALES, EMPHASIS-HF, and TOPCAT. JACC Heart Fail. 2019; 7(12):1012-1021. DOI: 10.1016/j.jchf.2019.08.017. View

Bakris G, Agarwal R, Chan J, Cooper M, Gansevoort R, Haller H . Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015; 314(9):884-94. DOI: 10.1001/jama.2015.10081. View

Saxena P . Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol. 1992; 19 Suppl 6:S80-8. DOI: 10.1097/00005344-199219006-00013. View

Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K . Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharmacol. 2015; 761:226-34. DOI: 10.1016/j.ejphar.2015.06.015. View

10.

Morris D, Latif S, Hardy M, Brem A . Endogenous inhibitors (GALFs) of 11beta-hydroxysteroid dehydrogenase isoforms 1 and 2: derivatives of adrenally produced corticosterone and cortisol. J Steroid Biochem Mol Biol. 2007; 104(3-5):161-8. DOI: 10.1016/j.jsbmb.2007.03.020. View

11.

Wada T, Inagaki M, Yoshinari T, Terata R, Totsuka N, Gotou M . Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol. 2020; 25(2):120-130. PMC: 7880964. DOI: 10.1007/s10157-020-01963-z. View

12.

Whittaker A, Kragh A, Hartleib-Geschwindner J, Albayaty M, Backlund A, Greasley P . Safety, Tolerability, and Pharmacokinetics of the Mineralocorticoid Receptor Modulator AZD9977 in Healthy Men: A Phase I Multiple Ascending Dose Study. Clin Transl Sci. 2019; 13(2):275-283. PMC: 7070793. DOI: 10.1111/cts.12705. View

13.

Yamada M, Takei M, Suzuki E, Takakusa H, Kotsuma M, Washio T . Pharmacokinetics, distribution, and disposition of esaxerenone, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist, in rats and monkeys. Xenobiotica. 2016; 47(12):1090-1103. DOI: 10.1080/00498254.2016.1263766. View

14.

Cleland J, Ferreira J, Mariottoni B, Pellicori P, Cuthbert J, Verdonschot J . The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart 'OMics' in AGEing (HOMAGE) randomized clinical trial. Eur Heart J. 2020; 42(6):684-696. PMC: 7878013. DOI: 10.1093/eurheartj/ehaa758. View

15.

Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C . Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol. 2015; 200:25-9. DOI: 10.1016/j.ijcard.2015.05.127. View

16.

Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S . Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019; 42(12):1932-1941. PMC: 8076031. DOI: 10.1038/s41440-019-0314-7. View

17.

Kurata A, Yoshida T, Inoue M, Ishizuka T, Nakatsu T, Shimizu T . Pharmacokinetics and Safety of Single-Dose Esaxerenone in Japanese Subjects with Mild to Moderate Hepatic Impairment. Adv Ther. 2019; 37(1):253-264. PMC: 6979450. DOI: 10.1007/s12325-019-01121-2. View

18.

Filippatos G, Bakris G, Pitt B, Agarwal R, Rossing P, Ruilope L . Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. J Am Coll Cardiol. 2021; 78(2):142-152. DOI: 10.1016/j.jacc.2021.04.079. View

19.

Williams B, MacDonald T, Morant S, Webb D, Sever P, McInnes G . Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018; 6(6):464-475. PMC: 5966620. DOI: 10.1016/S2213-8587(18)30071-8. View

20.

Cook C, Berry L, Bible R, Hribar J, Hajdu E, Liu N . Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans. Drug Metab Dispos. 2003; 31(11):1448-55. DOI: 10.1124/dmd.31.11.1448. View